Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II neoadjuvant abiraterone window-of-opportunity study in high-risk prostate cancer
2013-000674-30Phase 2Active
- Sponsor
- AOU San Luigi Gonzaga - SCDU Oncologia Medica
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of abiraterone in prostate cancer (PCa) (2 arms), sponsored by AOU San Luigi Gonzaga - SCDU Oncologia Medica. Primary endpoint: Pathological complete response plus almost complete response. Started May 2013; status: active.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-000674-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000674-30.